Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegaptanib + verteporfin
- Development stage
- Discontinued
- Lead developer
- Gilead Sciences
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Intravitreal (pegaptanib), Intravenous (verteporfin, For Pdt)
01
Overview
Combination of **pegaptanib**, an anti-VEGF aptamer that specifically inhibits the VEGF165 isoform, and **verteporfin**, a photosensitizer used in photodynamic therapy (PDT). Pegaptanib blocks vascular endothelial growth factor-mediated neovascularization and vascular permeability, while verteporfin, when activated by nonthermal laser light, generates reactive oxygen species leading to selective damage of abnormal neovascular tissue. This combination is investigated to synergistically treat choroidal neovascularization in wet age-related macular degeneration (AMD), aiming for improved efficacy and reduced retreatment frequency compared to monotherapy[1][2][4].
- Brand names
- Macugen
- Other names
- pegaptanib sodiumverteporfin PDT
02
Targets
LDLR (Low-density lipoprotein receptor)NRP1 (Neuropilin-1)VEGF-A165 (Vascular endothelial growth factor A isoform 165)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on pegaptanib + verteporfin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegaptanib + verteporfin.